Tumor-Targeted Erythrocyte Membrane Nanoparticles for Theranostics of Triple-Negative Breast Cancer.
Moon Jung ChoiYeon Kyung LeeKang Chan ChoiDo Hyun LeeHwa Yeon JeongSeong Jae KangMin Woo KimYoung Myoung YouChan Su ImYong Jin LeeYong Serk ParkPublished in: Pharmaceutics (2023)
Triple-negative breast cancer (TNBC) cells do not contain various receptors for targeted treatment, a reason behind the poor prognosis of this disease. In this study, biocompatible theranostic erythrocyte-derived nanoparticles (EDNs) were developed and evaluated for effective early diagnosis and treatment of TNBC. The anti-cancer drug, doxorubicin (DOX), was encapsulated into the EDNs and diagnostic quantum dots (QDs) were incorporated into the lipid bilayers of EDNs for tumor bio-imaging. Then, anti-epidermal growth factor receptor (EGFR) antibody molecules were conjugated to the surface of EDNs for TNBC targeting (iEDNs). According to the confocal microscopic analyses and biodistribution assay, iEDNs showed a higher accumulation in EGFR-positive MDA-MB-231 cancers in vitro as well as in vivo, compared to untargeted EDNs. iEDNs containing doxorubicin (iEDNs-DOX) showed a stronger inhibition of target tumor growth than untargeted ones. The resulting anti-EGFR iEDNs exhibited strong biocompatibility, prolonged blood circulation, and efficient targeting of TNBC in mice. Therefore, iEDNs may be used as potential TNBC-targeted co-delivery systems for therapeutics and diagnostics.
Keyphrases
- epidermal growth factor receptor
- cancer therapy
- poor prognosis
- tyrosine kinase
- advanced non small cell lung cancer
- drug delivery
- small cell lung cancer
- long non coding rna
- quantum dots
- photodynamic therapy
- induced apoptosis
- cell cycle arrest
- mass spectrometry
- high resolution
- small molecule
- liquid chromatography
- emergency department
- sensitive detection
- ionic liquid
- breast cancer cells
- computed tomography
- endoplasmic reticulum stress
- cell proliferation
- young adults
- high fat diet induced
- adverse drug